Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Miransertib in PROS or Proteus Syndrome
2022-500689-87-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of miransertib in PIK3CA-related overgrowth spectrum (PROS) and Proteus syndrome (PS), sponsored by Merck & Co. Primary endpoints: Number of participants experiencing a Serious Adverse Event (SAE) and Number of participants discontinuing study treatment due to an Adverse Event (AE). Planned start Jun 2022; status: authorised.
02
Drugs
miransertib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)Proteus syndrome (PS)
Beyond the preview
Go deeper on 2022-500689-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500689-87-00.